期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 19, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ijms19092545
关键词
prostate cancer; metastasis; LXRs; androgens; estrogens; cholesterol; oxysterols; signaling pathway
资金
- Region Auvergne-Rhone-Alpes
- Fond Europeen de Developpement Regional (FEDER)
- Association de Recherche sur les Tumeurs Prostatiques (ARTP)
- Fondation ARC
- Ligue contre le Cancer
- AAP Plan Cancer Environnement 2016 for SB-JMAL lab
Prostate cancer (PCa) incidence has been dramatically increasing these last years in westernized countries. Though localized PCa is usually treated by radical prostatectomy, androgen deprivation therapy is preferred in locally advanced disease in combination with chemotherapy. Unfortunately, PCa goes into a castration-resistant state in the vast majority of the cases, leading to questions about the molecular mechanisms involving the steroids and their respective nuclear receptors in this relapse. Interestingly, liver X receptors (LXR alpha/NR1H3 and LXR beta/NR1H2) have emerged as new actors in prostate physiology, beyond their historical roles of cholesterol sensors. More importantly LXRs have been proposed to be good pharmacological targets in PCa. This rational has been based on numerous experiments performed in PCa cell lines and genetic animal models pointing out that using selective liver X receptor modulators (SLiMs) could actually be a good complementary therapy in patients with a castration resistant PCa. Hence, this review is focused on the interaction among the androgen receptors (AR/NR3C4), estrogen receptors (ER alpha/NR3A1 and ER beta/NR3A2), and LXRs in prostate homeostasis and their putative pharmacological modulations in parallel to the patients' support.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据